Login to Your Account

Pfizer Abandoning Indiplon Deal; Neurocrine Falls Again

By Jennifer Boggs

Monday, June 26, 2006
A week after reporting that additional trials likely would be necessary for approval of its sleep drug, indiplon, Neurocrine Biosciences Inc. suffered another blow with the loss of its commercialization partner, Pfizer Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription